Series B
Matchpoint’s lead asset is the oral T cell modulator MPT-062, which the biotech plans to advance into clinical development for autoimmune and inflammatory conditions next year.
Biotechs that announced series B financing this year and are expanding their workforces include one that raised $2.1 billion and has partnerships with Eli Lilly, Johnson & Johnson and Novartis.
Biotechs that announced series B financing this year and are looking for employees as they grow include one that received over $100 million and another that has a partnership with a Big Pharma company.
With positive feedback on a Phase 3 trial design, Ollin Biosciences has collected a $330 million series B to advance its VEGF/Ang2 antibody, which bested Genentech’s therapy in a head-to-head study.
Biopharmas that announced Series B financing this year and are looking for employees as they grow include two companies that received $100 million or more. One has partnerships with three Big Pharmas.
Instead of using viral vectors, SonoThera’s genetic medicines are delivered through an ultrasound-mediated technology that could help sidestep key safety issues with conventional delivery methods.
City Therapeutics, one of BioSpace’s NextGen companies for 2026, was started by RNA royalty John Maraganore, former CEO of Alnylam.
CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical testing.
Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets.
Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the company claims improves their specificity and minimizes off-target effects.
PRESS RELEASES